9EP Stock Overview
A biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Enanta Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.75 |
| 52 Week High | US$16.10 |
| 52 Week Low | US$4.50 |
| Beta | 0.48 |
| 1 Month Change | -13.53% |
| 3 Month Change | 3.60% |
| 1 Year Change | -56.44% |
| 3 Year Change | -90.42% |
| 5 Year Change | -86.50% |
| Change since IPO | -56.09% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9EP | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -13.5% | 3.4% | 4.1% |
| 1Y | -56.4% | -10.0% | 17.2% |
Return vs Industry: 9EP underperformed the German Biotechs industry which returned -10% over the past year.
Return vs Market: 9EP underperformed the German Market which returned 17.2% over the past year.
Price Volatility
| 9EP volatility | |
|---|---|
| 9EP Average Weekly Movement | 12.5% |
| Biotechs Industry Average Movement | 9.2% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in DE Market | 12.1% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: 9EP's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 9EP's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 131 | Jay Luly | www.enanta.com |
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company’s product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir.
Enanta Pharmaceuticals, Inc. Fundamentals Summary
| 9EP fundamental statistics | |
|---|---|
| Market cap | €122.77m |
| Earnings (TTM) | -€95.85m |
| Revenue (TTM) | €60.83m |
2.0x
P/S Ratio-1.3x
P/E RatioIs 9EP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9EP income statement (TTM) | |
|---|---|
| Revenue | US$66.59m |
| Cost of Revenue | US$0 |
| Gross Profit | US$66.59m |
| Other Expenses | US$171.52m |
| Earnings | -US$104.93m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 12, 2025
| Earnings per share (EPS) | -4.92 |
| Gross Margin | 100.00% |
| Net Profit Margin | -157.57% |
| Debt/Equity Ratio | 146.5% |
How did 9EP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/19 20:31 |
| End of Day Share Price | 2025/03/18 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Enanta Pharmaceuticals, Inc. is covered by 19 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Geoffrey Meacham | Barclays |
| Patrick Trucchio | Berenberg |